A Survey to Evaluate Early Experience From Patient and Care Partner on Injection and Device for KESIMPTA® Indicated for Multiple Sclerosis
Completed
Conditions studied: Multiple Sclerosis
In brief
This was a US-based, observational cross-sectional study with primary data collection via questionnaires directly administered to patients with MS receiving KESIMPTA and care partners of patients with MS (formal or informal)receiving KESIMPTA.
Key facts
- Study ID
- NCT05334472
- Run by
- Novartis Pharmaceuticals
- People needed
- 105
- Starts
- 2021-11-24
- Expected to finish
- 2023-02-15
- Last updated by the study team
- 2024-03-25
Who can join
Age: 18 and older, up to 100. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Novartis Investigative Site — East Hanover, New Jersey, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.